Sparsentan - Retrophin

Drug Profile

Sparsentan - Retrophin

Alternative Names: DARA; PS-433540; RE-021

Latest Information Update: 01 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin
  • Class Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Focal segmental glomerulosclerosis
  • Phase II IgA nephropathy
  • Discontinued Hypertension

Most Recent Events

  • 26 Oct 2018 Additional efficacy data from the phase II/III DUET trial in Focal segmental glomerulosclerosis released by Retrophin
  • 27 Sep 2018 Retrophin plans the phase III PROTECT clinical trial for IgA nephropathy in USA and Europe in the fourth quarter of 2018
  • 14 Jun 2018 Retrophin has patent protection for the use of sparsentan for treating IgA nephropathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top